Thirty-two patients with locally advanced bowel cancer received a short course of the immunotherapy drug pembrolizumab before ...

A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III ...

Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.

The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...

Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC). AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T ...

More adverse events of grade 3 or higher reported for participants receiving pembrolizumab-belzutifan than pembrolizumab-placebo ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Clinical trials frequently include multiple end points that ...